Joel Lexchin

Oct 3, 2024 | wellandtribune.ca | Iris Gorfinkel |Joel Lexchin |Joel Lexchin Contributors

While much has been said about the added public costs of universal pharmacare, there’s been far too little emphasis on the other costs continually paid from not having prescription drugs covered. The groundwork for a national pharmacare program is expected in the coming weeks in Bill C-64. It’s six pages are now in its final legislative leg, but its importance to the health of Canadians cannot be understated.

Oct 3, 2024 | stcatharinesstandard.ca | Iris Gorfinkel |Joel Lexchin |Joel Lexchin Contributors

While much has been said about the added public costs of universal pharmacare, there’s been far too little emphasis on the other costs continually paid from not having prescription drugs covered. The groundwork for a national pharmacare program is expected in the coming weeks in Bill C-64. It’s six pages are now in its final legislative leg, but its importance to the health of Canadians cannot be understated.

Oct 2, 2024 | msn.com | Joel Lexchin

Microsoft Cares About Your PrivacyMicrosoft and our third-party vendors use cookies to store and access information such as unique IDs to deliver, maintain and improve our services and ads. If you agree, MSN and Microsoft Bing will personalise the content and ads that you see. You can select ‘I Accept’ to consent to these uses or click on ‘Manage preferences’ to review your options and exercise your right to object to Legitimate Interest where used.

Oct 2, 2024 | tolerance.ca | Joel Lexchin

By Joel Lexchin, Professor Emeritus of Health Policy and Management, York University, Canada Patient advocacy groups are often funded through pharmaceutical companies, but there are currently no regulations governing disclosure of this potential conflict of interest. Read complete article© The Conversation -

Oct 2, 2024 | theconversation.com | Joel Lexchin

Patient groups should be playing a central role in Canada’s health-care system, advocating for their members by promoting the visibility of their conditions, pushing for more rapid and accurate diagnoses and lobbying for the introduction and funding of new treatments and drugs that may help relieve their members’ symptoms and extend their lives. However, all of this requires resources.